step 9 semaglutide Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Two Years on Semaglutide -

Diabetes, Obesity and Metabolism , 26 , 16-27

The Nature of Ischemic Optic Neuropathy: The condition involves a sudden, sharp restriction of microvascular blood flow supplying the optic nerve

Bankers estimate compounders are making as much as $1 billion in annual weight-loss drug sales, but the haul could be much higher given how little information is available

Many initial trials for GLP-1s excluded participants with a history of major depressive disorder or any significant psychiatric conditions

M1-dominant macrophages overproduce TNF- and IL-6, directly blocking insulin receptor signalling in metabolically active tissues [4]